R&D channel feed

Due to in­creas­ing com­pe­ti­tion, Gala­pa­gos’ CAR-T ex­its au­toim­mune dis­eases

Last year

FDA grants pri­or­i­ty re­view for Dupix­ent in COPD, sets June ap­proval de­ci­sion dead­line

Last year
FDA+

Clin­i­cal tri­al starts slowed to be­low pre-pan­dem­ic lev­els last year, IQVIA analy­sis finds

Last year
Cell/Gene Tx

Mod­er­na wants an ac­cel­er­at­ed ap­proval for its can­cer vac­cine — but it's wait­ing on three things

Last year
Pharma

Al­ny­lam CEO de­fends changes to cru­cial AT­TR tri­al: 'We re­al­ly are play­ing to win'

Last year

Amy­lyx’s ALS drug tastes bit­ter. What would make it bet­ter? More patent life

Last year
Pharma

Mod­er­na’s ‘year of tran­si­tion’: Chang­ing gears from Covid-19 to RSV as vac­cine ap­proval date looms

Last year
Pharma
Coronavirus

Re­searchers de­tail da­ta from first 15 au­toim­mune dis­ease pa­tients treat­ed with CAR-T — and out­stand­ing ques­tions

Last year
Cell/Gene Tx

Bavar­i­an Nordic drops can­cer vac­cine ef­forts to fo­cus on in­fec­tious dis­eases

Last year

Vi­iV's long-act­ing Cabe­nu­va beats out dai­ly oral HIV treat­ments in PhI­II

Last year
Pharma

FDA paus­es RAPT Ther­a­peu­tics’ im­munol­o­gy drug stud­ies af­ter pa­tient ex­pe­ri­ences liv­er fail­ure

Last year
FDA+

The $100 bil­lion club gets a shake­up, dri­ven by biotech’s new blue-chip names

Last year
Pharma

As­traZeneca’s Tagris­so hits the mark in late-stage lung can­cer main­te­nance study

Last year

NodThera touts po­ten­tial weight loss ef­fect of NL­RP3 in­hibitors

Last year

De­nali re­ports a PhII ALS fail as RIPK1 deal with Sanofi hits an­oth­er bump

Last year

Af­ter pa­tient out­cry, Taysha starts to of­fload drug pro­grams

Last year
Cell/Gene Tx

In­ven­ti­va stock sinks 20% af­ter se­ri­ous ad­verse event in NASH tri­al leads to en­roll­ment pause

Last year

Gilead stops re­cruit­ment in CD47 sol­id tu­mor tri­als, a week af­ter it axed blood can­cer de­vel­op­ment

Last year

Up­dat­ed: Al­ny­lam de­lays high­ly-an­tic­i­pat­ed AT­TR read­out as it changes study de­sign

Last year

'Obe­si­ty plus': What’s next for GLP-1s?

Last year
In Focus

Au­rinia fails to find buy­er, will shed pipeline to fo­cus on Lup­ky­nis

Last year
People

Repli­cate Bio­science takes aim at mono-caus­ing virus af­ter promis­ing re­sults with mR­NA ra­bies shot

Last year

Ahead of share­hold­er vote on SQZ as­set sale and liq­ui­da­tion, founder Ar­mon Sharei says he will vote yes

Last year
People

Roivant dis­con­tin­ues blood can­cer pro­gram as it fails to re­vive old Ei­sai drug, to dis­solve Hema­vant

Last year
First page Previous page 51525354555657 Next page Last page
A service from the Financial Times